Blog
Post 6: Board Dynamics During Crisis — Oversight Under Pressure By Al Parker Crisis is the ultimate test of a board’s leadership and judgment. Whether it’s an adverse regulatory decision that halts a pipeline program, negative clinical trial results threatening years of investment, an activist shareholder campaign challenging strategic direction, a cybersecurity breach exposing sensitive…
Post 5: Independent but Informed: How Directors Can Add Value Without Losing Their Objectivity By Al Parker Independence is a bedrock principle of good governance. Shareholders, regulators, and management teams alike expect independent directors to bring impartial judgment, challenge assumptions, and protect the organization’s long-term interests. Yet independence alone is not enough. Boards also need…
Post 4: Governance Lessons from M&A, Licensing, and Joint Ventures By Al Parker Strategic transactions are moments of truth for boards. While mergers, acquisitions, licensing deals, and joint ventures can create extraordinary value, or they also could expose an organization to existential risk. In life sciences, where deals often involve complex intellectual property, regulatory considerations,…
Post 3: The Intersection of Governance and Compliance: What Directors in Regulated Industries Must Get Right By Al Parker In regulated industries like life sciences, healthcare, and financial services, boards walk a delicate tightrope. On one side lies governance and the board’s responsibility to oversee strategy, risk, and leadership effectiveness. On the other lies compliance…
Post 2: Navigating Strategic Risk in Life Sciences — A Director’s Playbook By Al Parker Risk underpins every strategic decision in the life sciences. Scientific uncertainty, clinical trial outcomes, regulatory complexity, commercial volatility, and shifting capital markets create an operating environment where value can be generated, or lost, at high speed. For corporate boards, especially…